(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 1,094.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Immunitybio's revenue in 2024 is $302,000.On average, 2 Wall Street analysts forecast IBRX's revenue for 2024 to be $49,485,837,017, with the lowest IBRX revenue forecast at $24,421,339,407, and the highest IBRX revenue forecast at $74,551,026,196. On average, 2 Wall Street analysts forecast IBRX's revenue for 2025 to be $191,830,578,862, with the lowest IBRX revenue forecast at $170,519,912,144, and the highest IBRX revenue forecast at $213,141,245,580.
In 2026, IBRX is forecast to generate $360,463,202,040 in revenue, with the lowest revenue forecast at $357,955,576,614 and the highest revenue forecast at $362,971,519,035.